Web Reference: Kazia is an Australian oncology company developing innovative, high-impact drugs for cancer. Our lead program is paxalisib, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Kazia is an Australian oncology company developing innovative, high-impact drugs for cancer. Our lead program is paxalisib, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. GBM AGILE trial data shows clinically meaningful improvement in a prespecified secondary analysis for overall survival in paxalisib-treated, newly diagnosed unmethylated patients with glioblastoma Sydney, July 10, 2024 -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce results from GBM-AGILE, a phase II/III study that included an ...
YouTube Excerpt: Welcome To MorphMarket Vlog-59 MOST Expensive
Color Profile Overview
Super Ball Python Unboxing Color Color Trends 2026: Meanings, Combinations, And Trends Explained Color & Biography
style: $30M - $74M
Salary & Income Sources
Career Highlights & Achievements
Assets, Properties & Investments
This section covers known assets, real estate holdings, luxury vehicles, and investment portfolios. Data is compiled from public records, financial disclosures, and verified media reports.
Last Updated: April 3, 2026
Color Outlook & Future Earnings
Disclaimer: Disclaimer: Color estimates are based on publicly available data, media reports, and financial analysis. Actual numbers may vary.